Baseline [18F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model

[1]  P. V. Bramhachari,et al.  Hypoxia inducible factor-1α: Its role in colorectal carcinogenesis and metastasis. , 2015, Cancer letters.

[2]  N. Petrelli,et al.  A review of the evolution of systemic chemotherapy in the management of colorectal cancer. , 2015, Clinical colorectal cancer.

[3]  Kenneth A Krohn,et al.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. , 2015, Seminars in nuclear medicine.

[4]  J. Bussink,et al.  Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[5]  B. Fuchs,et al.  Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models , 2013, The Journal of Nuclear Medicine.

[6]  Debby Laukens,et al.  Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake? , 2013, Molecular imaging.

[7]  A. Massaro,et al.  Colorectal cancer: prognostic role of 18F-FDG-PET/CT , 2012, Abdominal Imaging.

[8]  S. Wedge,et al.  An Evaluation of 2-deoxy-2-[18F]Fluoro-D-Glucose and 3′-deoxy-3′-[18F]-Fluorothymidine Uptake in Human Tumor Xenograft Models , 2012, Molecular Imaging and Biology.

[9]  Philippe Lambin,et al.  Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging , 2011, Proceedings of the National Academy of Sciences.

[10]  Yon Hui Kim,et al.  Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase , 2011, Cancer Chemotherapy and Pharmacology.

[11]  Kingshuk Roy Choudhury,et al.  A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  S. Dewilde,et al.  Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model. , 2009, Cancer letters.

[13]  G. Song,et al.  Role of hypoxia in the hallmarks of human cancer , 2009, Journal of cellular biochemistry.

[14]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[15]  E. Monti,et al.  Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. , 2009, European journal of cancer.

[16]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[17]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[18]  Tim A D Smith,et al.  Colorectal Tumor Cells Treated with 5-FU, Oxaliplatin, Irinotecan, and Cetuximab Exhibit Changes in 18F-FDG Incorporation Corresponding to Hexokinase Activity and Glucose Transport , 2008, Journal of Nuclear Medicine.

[19]  Johan Bussink,et al.  Aerobic glycolysis in cancers: Implications for the usability of oxygen‐responsive genes and fluorodeoxyglucose‐PET as markers of tissue hypoxia , 2008, International journal of cancer.

[20]  Kenneth A Krohn,et al.  Molecular Imaging of Hypoxia , 2008, Journal of Nuclear Medicine.

[21]  G. Hutchins,et al.  Monitoring chemotherapeutic response in RIF-1 tumors by single-quantum and triple-quantum-filtered (23)Na MRI, (1)H diffusion-weighted MRI and PET imaging. , 2007, Magnetic resonance imaging.

[22]  D. Kirkpatrick,et al.  Thioredoxin signaling as a target for cancer therapy. , 2007, Current opinion in pharmacology.

[23]  M. Picchio,et al.  Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine , 2007, Journal of Nuclear Medicine.

[24]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[25]  C. Dang,et al.  Effects of hypoxia on tumor metabolism , 2007, Cancer and Metastasis Reviews.

[26]  S. Green,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[27]  W. Oyen,et al.  Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  G. Semenza,et al.  Development of novel therapeutic strategies that target HIF-1 , 2006, Expert opinion on therapeutic targets.

[29]  Simon M. Ametamey,et al.  NanoPET imaging of [18F]fluoromisonidazole uptake in experimental mouse tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  K. Krohn,et al.  A new synthesis of the labeling precursor for [18F]- fluoromisonidazole , 2005 .

[31]  R. Gillies,et al.  The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[33]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[34]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[35]  G. Peters,et al.  Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma , 2003, British Journal of Cancer.

[36]  Qimin He,et al.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.

[37]  D. Kirkpatrick,et al.  The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. , 2003, Molecular cancer therapeutics.

[38]  S. Gambhir.  Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[39]  L. Bentzen.  Feasibility of Detecting Hypoxia in Experimental Mouse Tumours with 18F-fluorinated Tracers and Positron Emission Tomography: A Study Evaluating [18F]Fluoromisonidazole and [18F]Fluoro-2-deoxy-D-glucose , 2000 .

[40]  J. Overgaard,et al.  Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose. , 2000, Acta oncologica.

[41]  B. Teicher,et al.  Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. , 1995, The cancer journal from Scientific American.